Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR1 | Q8TCW9 | 6/20 | 0.41 |
| ▸ | PDE2A | O00408 | 2/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | CLPP | Q16740 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4092434 | 1.00 | PROKR1 (0.41) | PROKR1PDE2APDE3AMAP3K12HSD11B1 | |
| SCHEMBL4100606 | 0.89 | CYP11B1 (0.40) | PDE2APDE3AHSD11B1CYP11B1CYP11B2 | |
| SCHEMBL4100600 | 0.89 | CYP11B1 (0.40) | PDE2APDE3AHSD11B1CYP11B1CYP11B2 | |
| SCHEMBL4090649 | 0.89 | GRM5 (0.50) | PDE2APDE3AHSD11B1RAB9AGRM5 | |
| SCHEMBL4090653 | 0.89 | GRM5 (0.50) | PDE2APDE3AHSD11B1RAB9AGRM5 | |
| SCHEMBL1969685 | 0.89 | PROKR1 (0.45) | PROKR1HSD11B1RAB9AGRM5CLPP | |
| SCHEMBL1969678 | 0.89 | PROKR1 (0.45) | PROKR1HSD11B1RAB9AGRM5CLPP | |
| SCHEMBL1972877 | 0.87 | PROKR1 (0.46) | PROKR1HSD11B1 | |
| SCHEMBL1973907 | 0.87 | PROKR1 (0.47) | PROKR1HSD11B1RAB9A | |
| SCHEMBL1972874 | 0.87 | PROKR1 (0.46) | PROKR1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203737-A1 | Pyrrole Derivatives as Positive Allosteric Modulators of Metabotropic Receptors | ADDEX PHARMA SA (CH) | 2009-08-13 | — | — | US | claimed |
| US-20090203737-A1 | Pyrrole Derivatives as Positive Allosteric Modulators of Metabotropic Receptors | ADDEX PHARMA SA (CH) | 2009-08-13 | — | — | US | disclosed |
| US-20090203737-A1 | Pyrrole Derivatives as Positive Allosteric Modulators of Metabotropic Receptors | ADDEX PHARMA SA (CH) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203737-A1 | Pyrrole Derivatives as Positive Allosteric Modulators of Metabotropic Receptors | GRM5, GRIK5, GRM2 | PROKR1 1017/4885PDE2A 1038/4885PDE3A 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.